Literature DB >> 3934921

Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients.

P Knudsen, L B Hansen, K Højholdt, N E Larsen.   

Abstract

In order to investigate the feasibility of administering perphenazine decanoate (PD) at three week intervals the 42 patients participating in the previously reported open, prospective 12 month study were, after six months, treated according to the following scheme: 21 patients continued to receive injections every two weeks (group I), whereas in the remaining 21 patients the intervals between injections were extended to 3 weeks (group II). Both groups continued to respond equally well to therapy. Moreover it was observed that the mean daily dose of perphenazine was significantly reduced when using 3 weeks intervals. This study demonstrates that PD administered every 3 weeks is a safe and effective remedy for maintenance therapy in psychotic patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3934921

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  5 in total

Review 1.  Perphenazine for schizophrenia.

Authors:  Benno Hartung; Stephanie Sampson; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2015-03-06

Review 2.  Depot pipotiazine palmitate and undecylenate for schizophrenia.

Authors:  M Dinesh; A David; S N Quraishi
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

Review 3.  Depot perphenazine decanoate and enanthate for schizophrenia.

Authors:  A David; S Quraishi; J Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

4.  A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration.

Authors:  Mirjam Talvik; Anna-Lena Nordström; Niels-Erik Larsen; Aurelija Jucaite; Simon Cervenka; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

Review 5.  Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.

Authors:  Giuseppe Rossi; Sonia Frediani; Roberta Rossi; Andrea Rossi
Journal:  BMC Psychiatry       Date:  2012-08-21       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.